Harjit Gill - ResMed Independent Director
RMD Stock | USD 177.61 3.78 2.17% |
Director
Ms. Harjit Gill is Director of the company. Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed board after serving on it since July 1994. Ms. Gill appointment and Dr. Pace retirement both took effect Thursday, November 15. Ms. Gill has more than 25 years experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Philips ASEAN Pacific, overseeing HealthcareLighting and Consumer Lifestyle Products senior vice president of International Sales vice president of Asia for Philips Consumer Lifestyle Products and various other senior roles in Philips Consumer Electronics businesses in the Netherlands, Hong Kong, Dubai and Singapore. From 2015 to 2016, she served as chief operations and marketing officer for HTC, Taiwan. Since 2016, she was advisor to Delmedica Investments, a Singaporebased company focused on respiratory health and inventors of the XHalo breath thermometer. Ms. Gill is also a board director for Apollo Education and Training, a private company providing English teaching in Vietnam, and has held various leadership roles at the Singapore chapter of YPO, which provides growth and networking opportunities to CEOs worldwide. since 2018.
Age | 55 |
Tenure | 6 years |
Address | 9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123 |
Phone | 858-836-5000 |
Web | https://www.resmed.com |
ResMed Management Efficiency
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Craig Thompson | Charles River Laboratories | 64 | |
Richard Reese | Charles River Laboratories | 75 | |
Robert Bertolini | Charles River Laboratories | 59 | |
Hans Maerki | Mettler Toledo International | 71 | |
David Walt | Illumina | 62 | |
Virginia Wilson | Charles River Laboratories | 66 | |
Francis deSouza | Illumina | 53 | |
Thomas Salice | Mettler Toledo International | 61 | |
Robert Epstein | Illumina | 62 | |
Jeffrey Huber | Illumina | 46 | |
Tyler Jacks | Thermo Fisher Scientific | 59 | |
Sue Rataj | Agilent Technologies | 63 | |
Stanley Meresman | Guardant Health | 71 | |
Thomas Salice | Waters | 61 | |
Heidi Kunz | Agilent Technologies | 66 | |
Michael Berendt | Waters | 71 | |
Samir Kaul | Guardant Health | 44 | |
Hans Bishop | Agilent Technologies | 56 | |
Sperling Sperling | Thermo Fisher Scientific | 58 | |
Lars Sorensen | Thermo Fisher Scientific | 67 | |
Daniel Podolsky | Agilent Technologies | 67 |
Management Performance
Return On Equity | 0.22 | ||||
Return On Asset | 0.11 |
ResMed Inc Leadership Team
Elected by the shareholders, the ResMed's board of directors comprises two types of representatives: ResMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ResMed. The board's role is to monitor ResMed's management team and ensure that shareholders' interests are well served. ResMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ResMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bobby Ghoshal, Chief Technology Officer, President - SaaS business | ||
AM BE, Chair Founder | ||
John Wareham, Independent Director | ||
Ronald Taylor, Lead Independent Director | ||
Michael Rider, Chief Officer | ||
Gary Pace, Independent Director | ||
Agnes Lee, Senior Director - Investor Relations | ||
Vered Keisar, Chief Officer | ||
Harjit Gill, Independent Director | ||
Kaushik Ghoshal, Chief SaaS | ||
Carol Burt, Independent Director | ||
Rich Sulpizio, Independent Director | ||
Peter Farrell, Non-Executive Chairman of the Board | ||
Jim Hollingshead, President – sleep and respiratory care business | ||
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit | ||
Jack Wareham, Independent Director | ||
Jan Witte, Independent Director | ||
Rajwant Sodhi, President – Software as a Service Business (SaaS) | ||
BE MBA, CEO Director | ||
Anne Reiser, President Europe | ||
Karen Drexler, Independent Director | ||
AM AM, Founder Chairman | ||
Richard McHale, President – Respiratory Care Business | ||
Donald Darkin, President – innovation & operations | ||
Constance Bienfait, Director Relations | ||
Urvashi Tyagi, Chief Technology Officer | ||
Rob Douglas, President COO | ||
Justin Leong, President – Asia and Latin America | ||
Christopher Roberts, Independent Director | ||
Chris Roberts, Independent Director | ||
Robert Douglas, President, Chief Operating Officer | ||
YvonneKatrin Pucknat, Chief Officer | ||
Amy Wakeham, VP Communications | ||
Brett Sandercock, CFO and Principal Accounting Officer | ||
Ron Taylor, Lead Independent Director | ||
Raj Sodhi, President – Software as a Service (SaaS) Business and CTO | ||
David Pendarvis, Chief Administrative Officer, Global General Counsel, Secretary | ||
Richard Sulpizio, Independent Director | ||
Michael Farrell, Chief Executive Officer, Director | ||
Jim Ellis, Chief Officer |
ResMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ResMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.22 | ||||
Return On Asset | 0.11 | ||||
Profit Margin | 0.20 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 28.36 B | ||||
Shares Outstanding | 147.09 M | ||||
Shares Owned By Insiders | 0.81 % | ||||
Shares Owned By Institutions | 57.18 % | ||||
Number Of Shares Shorted | 7.89 M | ||||
Price To Earning | 73.48 X |
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.04 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.